ICU sedation, delirium & recovery
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU
Authors' conclusion
ICU admission rates after CAR T-cell treatment are declining. Although ICU patients are older with higher severity of illness and toxicity grades, ICU mortality after CAR T-cell therapy remains low.
Study context
- Population
- Adult chimeric antigen receptor (CAR) T-cell patients requiring ICU admission, 8 US centers, January 2018 to September 2023398 (17.8%) required ICU
- Participants
- 2,238 patients
- Exposure
- ICU admission, management and outcomes year-to-year, 2023 vs 2018
- Outcome
- ICU admission rate
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
P < 0.0001
Observational data: associations, not effects.
Further findings
Age of ICU patients, 2023 vs 2018
P = 0.003
Toxicity ≥ grade 3 in ICU patients, 2023 vs 2018
P = 0.004
Factors associated with hospital mortality (multivariable logistic regression)
| OR (95% CI) | P value | ||
|---|---|---|---|
| Age | 1.02 (1–1.04) | P = 0.046 | |
| SOFA ≥ 10 at ICU admission | 4.69 (2.44–9.01) | P < 0.0001 | |
| 0.10.31310Odds ratio (log scale) |
| Outcome | 2023 | 2018 | P value |
|---|---|---|---|
| Comorbidity index of ICU patients, 2023 vs 2018 | 4 (IQR 4–6) | 3 (IQR 2–4) | P = 0.005 |
Corticosteroid use for ≤ grade 2 toxicity
- Increased throughout the years
- 73.8% vs. 40.6%; p = 0.0001
Anakinra use
- Increased throughout the years
- 56% vs. 5.5%; p < 0.0001
CRS or ICANS as reason for ICU admission
- Reason for ICU admission
- 87.9%
Mortality from CRS and ICANS
- Remained low
- 5.5%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →